Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Chief Medical Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 224,215 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 11,447 · Balance 224,215 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 21:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,447 | $12.97 | $148,467.59 |
DisclosureSEC source: 0001104659-26-095006 · tm2623037-2_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,215 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,023 | $5.08 | $71,236.84 |
DisclosureSEC source: 0001104659-26-064526 · tm2615137-6_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,662 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $5.01 to $5.08 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:10 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040575 · tm2611350-13_4seq1.xml · derivative · entry 2 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:10 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-040575 · tm2611350-13_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,685 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:13 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-123286 · tm2533977-4_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,685 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 50% of the RSUs will vest on November 15, 2026 and 50% of the RSUs will vest on November 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,248 | $9.10 | $65,956.80 |
DisclosureSEC source: 0001104659-25-114122 · tm2531717-1_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,685 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares calculated by the broker executing the sell-to-cover transactions. The Shares were sold as part of a block trade in multiple transactions at prices ranging from $8.88 to $9.26 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:46 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,952 | $8.06 | $64,093.12 |
DisclosureSEC source: 0001104659-25-052145 · tm2515608-6_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,933 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-25-031832 · tm2511407-8_4seq1.xml · derivative · entry 2 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2035-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031832 · tm2511407-8_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,885 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| November 18, 2024 Filed Nov 21, 2024 02:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,246 | $10.78 | $78,111.88 |
DisclosureSEC source: 0001104659-24-121188 · tm2429047-2_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,885 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 15,881 | $7.50 | $119,107.50 |
DisclosureSEC source: 0001104659-24-070108 · tm2416882-1_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,131 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on February 13, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.55. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 117,131 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 266,750 shares of the Issuer's common stock, 84,280 of which are exercisable as of the date hereof. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 6,367 | $6.47 | $41,194.49 |
DisclosureSEC source: 0001104659-24-063558 · tm2414961-1_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,012 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043256 · tm2410652-9_4seq1.xml · derivative · entry 2 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 26,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-043256 · tm2410652-9_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,379 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| November 16, 2023 Filed Nov 18, 2023 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,313 | $10.92 | $79,857.96 |
DisclosureSEC source: 0001104659-23-119646 · tm2331094-1_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,714 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.92 to $11.09. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 771 | $18.05 | $13,916.55 |
DisclosureSEC source: 0001104659-23-062373 · tm2316199-4_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,027 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.21. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041726 · tm2311410-7_4seq1.xml · derivative · entry 2 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041726 · tm2311410-7_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,798 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001104659-22-124656 · tm2231933-2_4seq1.xml · derivative · entry 2 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2032-12-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on December 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-124656 · tm2231933-2_4seq1.xml · nonDerivative · entry 1 Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,798 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on November 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.